GlassScriptPhysician profile
Tina Wong
NPI 1497847578
$9,334.04
in general payments reported to CMS, 2019-2025
40 companies · $1,362 in 2025
The $1,362 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,371 · 2020: $1,387 · 2021: $1,395 · 2022: $1,256 · 2023: $1,358 · 2024: $1,205 · 2025: $1,362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,925.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,924.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,116.29 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Merck Sharp & Dohme LLC | $1,036.44 | 2019-2025 | Verquvo, Gardasil 9, Belsomra |
| Gilead Sciences, INC. | $794.49 | 2019-2025 | |
| Lilly USA, LLC | $612.55 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $525.55 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $453.08 | 2019-2025 | Jardiance |
| Abbvie INC. | $398.89 | 2019-2025 | Viberzi, Linzess |
| Glaxosmithkline, LLC. | $389.63 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amarin Pharma, INC. | $379.32 | 2019-2023 | |
| Pfizer INC. | $378.05 | 2020-2025 | |
| Abbott Laboratories | $331.37 | 2019-2021 | |
| Biotronik INC. | $219.78 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $217.47 | 2019-2024 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $208.00 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $202.07 | 2021-2023 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tina Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.